{"pmid":32208840,"title":"Clinical observation and management of COVID-19 patients.","text":["Clinical observation and management of COVID-19 patients.","Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient.","Emerg Microbes Infect","Li, Taisheng","Lu, Hongzhou","Zhang, Wenhong","32208840"],"abstract":["Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient."],"journal":"Emerg Microbes Infect","authors":["Li, Taisheng","Lu, Hongzhou","Zhang, Wenhong"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32208840","week":"202013|Mar 23 - Mar 29","doi":"10.1080/22221751.2020.1741327","keywords":["Clinical management","SARS","SARS-CoV-2","antiviral drugs","coronavirus"],"source":"PubMed","locations":["Chinese","Shanghai","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662444220160409600,"score":7.208847,"similar":[{"pmid":32196410,"title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia.","text":["Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed.","Emerg Microbes Infect","Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng","32196410"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed."],"journal":"Emerg Microbes Infect","authors":["Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196410","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1746199","keywords":["Anticoagulation","COVID-19","IVIg","Pathogenesis","SARS-CoV-2"],"source":"PubMed","locations":["China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1662334543081766912,"score":218.7272},{"pmid":32145718,"title":"[Healing the schism between public health and medicine, promoting the integration of prevention and treatment].","text":["[Healing the schism between public health and medicine, promoting the integration of prevention and treatment].","The 'Healing the Schism: Epidemiology, Medicine, and the Public's Health' by professor Kerr L. White's be published has a history of nearly 30 years. Since then, although scholars have appealed to incorporating public health and clinical medicine education, and breaking down separations between public health and clinical workforce in China, the effect is yet not so obvious. The outbreak of coronavirus disease 2019 (COVID-19) has opened a public class on the treatment, prevention and control of infectious diseases for the Chinese citizens. Consequently, the Chinese people have higher expectations on the modernization of public health governance, and the social atmosphere of incorporating preventive medicine and clinical medical education is establishing. In future, when combating with novel infectious diseases and public health emergencies, the response capacity of public health system and treatment capacity of clinical system will be significantly improved, while the situation on insufficient integration of prevention and treatment is bound to be reversed.","Zhonghua Yu Fang Yi Xue Za Zhi","Tao, F B","32145718"],"abstract":["The 'Healing the Schism: Epidemiology, Medicine, and the Public's Health' by professor Kerr L. White's be published has a history of nearly 30 years. Since then, although scholars have appealed to incorporating public health and clinical medicine education, and breaking down separations between public health and clinical workforce in China, the effect is yet not so obvious. The outbreak of coronavirus disease 2019 (COVID-19) has opened a public class on the treatment, prevention and control of infectious diseases for the Chinese citizens. Consequently, the Chinese people have higher expectations on the modernization of public health governance, and the social atmosphere of incorporating preventive medicine and clinical medical education is establishing. In future, when combating with novel infectious diseases and public health emergencies, the response capacity of public health system and treatment capacity of clinical system will be significantly improved, while the situation on insufficient integration of prevention and treatment is bound to be reversed."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Tao, F B"],"date":"2020-03-09T11:00:00Z","year":2020,"_id":"32145718","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.cn112150-20200304-00246","keywords":["COVID-19","Education, medical","Public health"],"source":"PubMed","locations":["China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1662334543911190528,"score":210.0472},{"pmid":32205349,"title":"Updated approaches against SARS-CoV-2.","text":["Updated approaches against SARS-CoV-2.","The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in the virology, epidemiology and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing towards the development of treatment for COVID-19. Recent studies have revealed many attractive threptic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. In this minireview, we aim to summarize the updated potential approaches against SARS-CoV-2. We emphasize that further efforts are warranted to develop the safest and most effective approach.","Antimicrob Agents Chemother","Li, Haiou","Zhou, Yunjiao","Zhang, Meng","Wang, Haizhou","Zhao, Qiu","Liu, Jing","32205349"],"abstract":["The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in the virology, epidemiology and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing towards the development of treatment for COVID-19. Recent studies have revealed many attractive threptic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. In this minireview, we aim to summarize the updated potential approaches against SARS-CoV-2. We emphasize that further efforts are warranted to develop the safest and most effective approach."],"journal":"Antimicrob Agents Chemother","authors":["Li, Haiou","Zhou, Yunjiao","Zhang, Meng","Wang, Haizhou","Zhao, Qiu","Liu, Jing"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205349","week":"202013|Mar 23 - Mar 29","doi":"10.1128/AAC.00483-20","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543364882432,"score":180.52248},{"pmid":32167823,"title":"Potential global pandemics: the role of the WHO and other public health bodies.","text":["Potential global pandemics: the role of the WHO and other public health bodies.","In light of the emergence of the new coronavirus in China, Emeritus Professor Alan Glasper, from the University of Southampton, discusses the response strategies adopted by international and national public health agencies.","Br J Nurs","Glasper, Alan","32167823"],"abstract":["In light of the emergence of the new coronavirus in China, Emeritus Professor Alan Glasper, from the University of Southampton, discusses the response strategies adopted by international and national public health agencies."],"journal":"Br J Nurs","authors":["Glasper, Alan"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167823","week":"202011|Mar 09 - Mar 15","doi":"10.12968/bjon.2020.29.5.322","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1662334543715106817,"score":176.66049},{"pmid":32220112,"title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.","text":["Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.","BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, the application of heparin in COVID-19 has been recommended by some expert consensus due to the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications and outcomes of consecutive patients being classified as severe COVID-19 in Tongji hospital were retrospectively analysed. The 28-day mortality between heparin users and nonusers were compared, also in different risk of coagulopaphy which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin, LMWH) for 7 days or longer. The D-dimer, prothrombin time and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference on 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P=0.910). But the 28-day mortality of heparin users were lower than nonusers In patients with SIC score >/=4 (40.0% vs 64.2%, P=0.029), or D-dimer > 6 fold of upper limit of normal (32.8% vs 52.4%, P=0.017). CONCLUSIONS: Anticoagulant therapy mainly with LMWH appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.","J Thromb Haemost","Tang, Ning","Bai, Huan","Chen, Xing","Gong, Jiale","Li, Dengju","Sun, Ziyong","32220112"],"abstract":["BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, the application of heparin in COVID-19 has been recommended by some expert consensus due to the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications and outcomes of consecutive patients being classified as severe COVID-19 in Tongji hospital were retrospectively analysed. The 28-day mortality between heparin users and nonusers were compared, also in different risk of coagulopaphy which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin, LMWH) for 7 days or longer. The D-dimer, prothrombin time and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference on 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P=0.910). But the 28-day mortality of heparin users were lower than nonusers In patients with SIC score >/=4 (40.0% vs 64.2%, P=0.029), or D-dimer > 6 fold of upper limit of normal (32.8% vs 52.4%, P=0.017). CONCLUSIONS: Anticoagulant therapy mainly with LMWH appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer."],"journal":"J Thromb Haemost","authors":["Tang, Ning","Bai, Huan","Chen, Xing","Gong, Jiale","Li, Dengju","Sun, Ziyong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220112","week":"202013|Mar 23 - Mar 29","doi":"10.1111/jth.14817","keywords":["D-dimer","coagulopathy","coronavirus disease 2019","low molecular weight heparin","sepsis"],"source":"PubMed","locations":["Tongji","heparin"],"topics":["Treatment"],"weight":1,"_version_":1662540582126354432,"score":175.09438}]}